STAT3 and anemia: More recently, Sanikommu et al., in an updated analysis of clinical features and outcomes in 204 LGLL patients, with 66 out of 183 (36%) carrying mutations in STAT3, communicated that STAT3-mutated patients were more likely to develop neutropenia (62% vs. 37%), anemia (49% vs. 34%) and RA (29% vs. 9%) than STAT3-wild-type subjects [14].